Immunotherapy in NSCLC Pathologist role
|
|
- Shona Ray
- 5 years ago
- Views:
Transcription
1 Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital
2 Genetic alterations in NSCLC Khono et al, Trans Lung Cancer Res, 2015
3 Immune checkpoint pathway Maintenance of self tolerance in normal physiological conditions Can be dysregulate by tumor cell immune resistance T-cells key antitumor immunity selective recognition of peptides derived from proteins directly recognize and kill antigen-expressing cells orchestrate diverse immune responses
4 Immune checkpoint pathway + Co-stimulatory _ Inhibitory Pardoll et al, Nat Rev Cancer, 2016
5 Mechanism of tumor immune reaction Topalian et al, Nature reviews, 2016
6 Mechanisms for intratumoral PDL1 expression Topalian et al, Nature reviews, 2016
7 Consistent benefit in OS of Anti-PD-1 drugs Nivolumab Pembrolizumab Atezolizumab 1. Horn et al, J Clin oncol, 2017, 2. Brahmer et al, NEJM, 2016, 3. Rittmeyer et al, Lancet, 2017
8 Immune checkpoint inhibitors and matching PD-L1 assay Sao MS et al, IASLC 18th World Conference on Lung Cancer
9 PD-L1 immunohistochemistry (IHC) assays Sao MS et al, IASLC 18th World Conference on Lung Cancer
10 Goals: To compare analytical performance of 4 assays; 22C3, 28-8, SP142 and SP263 (using staining protocols in corresponding to clinical trials) To compare the treatment-determining scoring algorithm developed for each assays and used in clinical trials
11 PD-L1 expression on tumor cells
12 PD-L1 expression on immune cells
13 Overall percent agreement
14 Limitation of Blueprint 1 study
15
16 Goals of Blueprint phase 2 study
17 Material (Blueprint phase 2A)
18 Methods (Blueprint phase 2A)
19
20
21 Statistical Analyses Plan
22
23
24
25
26
27
28
29 Summary of Blueprint 2A
30 Ramathibodi data January 2017 to October 2017 PDL-1 IHC 22C3 assay 64 cases 14 strong positive (TPS 50%) 10 adenocarcinoma 1 squamous cell carcinoma 1 adenosquamous carcinoma 1 NSCLC, NOS 10 weak positive (TPS 1-49%) 40 negative
31 Scoring guidelines PD-L1 22C3 from DAKO All viable tumor cells on the entire slide must be evaluated Minimum of 100 viable tumor cells Determine percentage of viable tumor cells showing partial or complete membrane staining at any intensity (TPS) Cytoplasmic staining considered as non-specific staining Do not score immune cells
32 500 FFPE tissue archives establishes concordance between three validated, commercially available PD-L1 IHC diagnostic assays for NSCLC patients; Ventana SP263 (durvalumab), Dako 22C3 (pembrolizumab), and Dako 28-8 (nivolumab) An overall percentage agreement of >90% was achieved between assays at multiple expression cutoffs, including 1%, 10%, 25%, and 50% tumor membrane staining.
33 Ratcliffe et al, Clin Cancer research, 2017
34 JTO, November 2017 Serial sections from tissue microarrays from 100 lung adenocarcinomas, stained and scored in four centers. The overall concordances between 22C3 and SP263 data were 0.99
35 Agilent PD-L1 IHC 22C3 pharmdx and VENTANA PD-L1 (SP263) Assays 22C3 SP263 Reagents/Ab Mouse Monoclonal PD-L1 Rabbit Monoclonal PD-L1 Tissue type FFPE FFPE Preparation and Platform Recommended controls EnVision FLEX visualization system on Agillent Autostainer Link Control cell line (+/-) slide 2. Negative reagent control 3. Tissue control (+ and -) Slide thickness 4-5 micron 4-5 microns Maximum storage 6 months 12 months OptiView DAB IHC Detection kit, fully automated on VENTANA Benchmarks 1. No cell line control 2. Negative reagent control 3. Tissue control (+ and -) Counted cells Minimum 100 viable tumor cells No required minimum Apply from Targos webinar, October 2017
36 Agilent PD-L1 IHC 22C3 pharmdx and VENTANA PD-L1 (SP263) Assays 22C3 SP263 H&E Must be acceptable Must be acceptable Controls Must be acceptable Must be acceptable Counted cells Minimum of 100 No required minimum number of cells Scoring Tumor cells TPS (Tumor Proportion Score) expressed as a % % of tumor cells (TC) Immune cells (Ics) Do not score ICs Do not score ICs Intensity Any perceptable staining (partial or complete) Any intensity above background (partial or complete) Cytoplasmic staining Non-specific staining Non-specific staining Relevant cutoffs 1% 50% 1% 50%
37 TC >50%
38 TC <1%
39 22C3 <1%, SP263 1%
40 Conclusion Agilent PD-L1 22C3 IHC PharmDx and Ventana PD-L1 (SP263) assays are both approved for selection of patients for treatment with Pembrolizumab. Both assays results in several centers are interpretational high concordant and could be used interchangeably at relevant clinical cutoffs.
41 Benefit in OS with no known PD-L1 status Nivolumab Pembrolizumab Atezolizumab
42 Multifactorial biomarkers of clinical response to PD1 pathway blockade Topalian et al, Nature reviews, 2016
43 The prevalence of somatic mutations across human cancer types Alexandrov et al, Nature, 2013
44 Pitfalls of using PDL1 IHC as a biomarker test for anti-pd1 PDL1 therapy Focal PDL1 expression may be missed in small biopsy specimens PDL1 expression can vary over time and by anatomical site PDL1 expression in tumor biopsies collected months or years earlier might not accurately reflect PDL1 status at the time of treatment initiation Therapies given after biopsy but before administration of anti- PD1 may alter PDL1 expression PDL1 epitopes detected by some antibodies are potentially unstable with prolonged specimen fixation or inadequate tissue handling
45 Pitfalls of using PDL1 IHC as a biomarker test for anti-pd1 PDL1 therapy PDL1 can be expressed by multiple cell types within TME, which poses challenges for scoring and interpretation PDL1 expression is not absolutely predictive of response from anti -PD1 drug nevertheless identify patients with a greater likelihood of response, thereby guiding clinical decisionmaking for treatment sequencing
46
Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationAgilent companion diagnostics for cancer immunotherapy
Agilent companion diagnostics for cancer immunotherapy Annika Eklund, PhD Global Product Manager Companion Diagnostics Agilent Technologies Aalborg 1 Agilent Trusted Answers. Together OUR FOCUS life sciences,
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationBiomarkers for Cancer Immunotherapy Debate
Biomarkers for Cancer Immunotherapy Debate Moderator: Maria Karasarides, PhD AstraZeneca Pro: Daniel S. Chen, MD, PhD Genentech Con: Steve Averbuch, MD Bristol-Myers Squibb Biomarkers to Select Patients
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC
VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCorporate presentatie Maastricht UMC+ (titel presentatie)
Datum Corporate presentatie Maastricht UMC+ (titel presentatie) PDL1: een simpele kleuring? Titel Naam spreker van (optioneel) de presentatie Functie spreker (optioneel) Onderwerpregel Ernst Jan M. Speel,
More informationPD-L1 Expression, Role, and Significance in Lung Pathology. Ross A Miller, MD FACP FASCP
PD-L1 Expression, Role, and Significance in Lung Pathology Ross A Miller, MD FACP FASCP Background information PD-1 and PD-L1 expression in tissues PD-L1 Ligand to PD-1 (PD-1 on T cells) Rarely expressed
More informationOverview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade
Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationAssessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy
VENTANA PD-L1 (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA PD-L1 (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA PD-L1 (SP142) Assay Identify patients most
More informationVENTANA PD-L1 (SP142) Assay
VENTANA (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess UC patient benefit from TECENTRIQ
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationAssessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
More informationClinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors
Clinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors ESP/ESMO Marina Chiara GARASSINO Amsterdam 2017 September, 4th 29 European Congress of Pathology Disclosures BMS ROCHE
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationThe Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia
VASCULAR CELL OPEN ACCESS ORIGINAL RESEARCH The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia Pagliuso Julia, Parry Suzanne, Haffajee Zenobia, Badrick Tony, Miller Keith,
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationGLOBAL REGISTRATION STRATEGIES:
GLOBAL REGISTRATION STRATEGIES: Therapeutic Product (TP) and the Companion Diagnostic (CDx) Erin Pedalino Regulatory Affairs International MSD Unique Role as CDx Regulatory Liaison at a Therapeutic Product
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationNeoadjuvant Nivolumab in Early-Stage, Resectable Non-Small Cell Lung Cancers
Neoadjuvant Nivolumab in Early-Stage, Resectable Non-Small Cell Lung Cancers Abstract 8508 Chaft JE, Forde PM, Smith KN, Anagnostou V, Cottrell TR, Taube JM, Rekhtman N, Merghoub T, Jones DR, Hellmann
More informationIntegrazione in Anatomia Patologica dei markers predittivi nel NSCLC: l esperienza di PD-L1
Integrazione in Anatomia Patologica dei markers predittivi nel NSCLC: l esperienza di PD-L1 Dipartimento di Sanità Pubblica Università degli Studi di Napoli Federico II Dott. Antonino Iaccarino PDL1-Mechanism
More informationAssessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer
Original Article Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer Chen Pang 1 *, Limei Yin 1 *, Xiaojuan Zhou 1 *,
More informationInterpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use
Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use For countries outside of the United States, see the local
More informationDiagnostic & Predictive Immunohistochemistry in Lung Carcinomas
Diagnostic & Predictive Immunohistochemistry in Lung Carcinomas Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Associate Professor, Harvard Medical School Boston, MA Disclosures
More informationStrengths and Weaknesses of PD-L1 testing: Pathology perspective
Strengths and Weaknesses of PD-L1 testing: Pathology perspective Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Foresterhill, Aberdeen Disclosures
More informationVENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue VENTANA anti-mlh1 (M1) Mouse Monoclonal Primary Antibody VENTANA anti-pms2 (A16-4) Mouse Monoclonal Primary Antibody VENTANA
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationEmerging biomarkers for immunotherapy in lung cancer
Emerging biomarkers for immunotherapy in lung cancer Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Aberdeen, UK Why Do We Need Biomarkers for Immunotherapy?
More informationOptimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods
Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods Kelly A. Schats, PharmD; Emily A. Van Vré, PhD; Carolien Boeckx, PhD; Martine De
More informationApplying Emerging Immunotherapy Data to NSCLC Clinical Practice
Applying Emerging Immunotherapy Data to NSCLC Clinical Practice Jarushka Naidoo, MBBCH Upper Aerodigestive Division, Department of Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationConsistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
Scorer et al. Diagnostic Pathology (2018) 13:47 https://doi.org/10.1186/s13000-018-0725-9 RESEARCH Open Access Consistency of tumor and immune cell programmed cell death ligand-1 expression within and
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationUrothelial Carcinoma (UC)
EDUCATION PD-L1 IHC 28-8 pharmdx Interpretation Manual Urothelial Carcinoma (UC) PD-L1 IHC 28-8 pharmdx is FDA-approved for In Vitro Diagnostic Use Table of Contents Introduction...5 Intended Use in Urothelial
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationUrothelial Carcinoma (UC)
EDUCATION PD-L1 IHC 28-8 pharmdx Interpretation Manual Urothelial Carcinoma (UC) For In Vitro Diagnostic Use Table of Contents Introduction...5 Intended Use in Urothelial Carcinoma...5 How to Use the
More informationNSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA
Lung cancer and other malignancies -PD-L1 assay, QuIP EQA Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP 11.05.2018 NSCLC Harmonization
More informationImmunoterapia e farmaci innovativi
Immunoterapia e farmaci innovativi Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Padova, 29 Ottobre 2015 Disclosures Advisory
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More informationCarcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos
Carcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background Immunotherapy
More informationHistopathology 2016 DOI: /his.13056
Histopathology 216 DOI:.1111/his.1356 Validated programmed cell death ligand 1 immunohistochemistry assays ( and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationVENTANA PD-L1 (SP263) Assay Staining in Urothelial Carcinoma Interpretation Guide
VENTANA PD-L1 (SP263) Assay Staining in Urothelial Carcinoma Interpretation Guide 2 VENTANA PD-L1 (SP263) Assay in Urothelial Carcinoma Interpretation Guide Table of Contents Introduction 4 Intended Use
More informationWhat is new in Immunotherapy, Biomarkers and Side Effects
What is new in Immunotherapy, Biomarkers and Side Effects Prof Dr Christian Rolfo, MD, PhD, MBA Director of Phase I Early Clinical Trials Unit Director of Clinical Trial Management Program Oncology Department
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationFattori predittivi di efficacia ed interpretazione della risposta all immunoterapia. Dott. Matteo Brighenti Oncologia Cremona
Fattori predittivi di efficacia ed interpretazione della risposta all immunoterapia Dott. Matteo Brighenti Oncologia Cremona AREA DI RICERCA CLINICA EPIDEMIOLOGICA ONCOLOGIA CREMONA mos in 4 phase III
More informationMolecular classification of lung cancer for clinical practice
Centre Jean Perrin Centre de Lutte contre le Cancer d'auvergne Clermont-Ferrand - France - Molecular classification of lung cancer for clinical practice Frédérique Penault-Llorca In the beginning.. There
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationDeciphering the biology that drives response to immunotherapy
Deciphering the biology that drives response to immunotherapy Phenoptics TM Quantitative Pathology Platform Trent Norris, Field Application Scientist September 15, 2016 HUMAN HEALTH ENVIRONMENTAL HEALTH
More informationIMUNOTERAPIA NO CÂNCER DE PULMÃO: PRINCÍPIOS
IMUNOTERAPIA NO CÂNCER DE PULMÃO: PRINCÍPIOS Dr. Gilberto de Castro Junior Professor Colaborador Livre-Docente Faculdade de Medicina da USP. Serviço de Oncologia Clínica - Instituto do Câncer do Estado
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationInnovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1
Innovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1 Monday, October 17, 2016 MaRS Discovery District, Toronto This session was generously sponsored by Merck Canada
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationNordiQC External Quality Assurance in Immunohistochemistry
NordiQC External Quality Assurance in Immunohistochemistry Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark AALBORG (~ 200.000 inhabitants)
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More information07/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of
With main focus on the Estrogen Receptor Commentary The best way to achieve optimal treatment of today s patients is to ensure the availability of reliableand timelypathological th l i l assessment in
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationImmunohistochemistry for predictive biomarkers in non-small cell lung cancer
Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer Immunohistochemistry for predictive biomarkers in non-small cell lung cancer Mari Mino-Kenudson Department of Pathology, Massachusetts
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationVENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody. ALK IHC Biomarker Testing Aiding in patient diagnosis
VENTANA (D5F3) Rabbit Monoclonal Primary Antibody IHC Biomarker Testing Aiding in patient diagnosis 2 IHC Biomarker Testing Lung cancer is the leading cause of death Lung cancer is the most prevalent form
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationInmunoterapia en tumores digestivos no colorrectales
Inmunoterapia en tumores digestivos no colorrectales Santander, 13 de Julio del 2017 Maria Alsina, MD PhD Hospital Universitari Vall d Hebron Outline Introduction Hepatocarcinoma Pancreatic Cancer Gastric
More informationTITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma
TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Ms Amy Newman, Ms Suzanne Parry, Mrs Dawn Wilkinson, Dr Tony O Grady, Dr Perry Maxwell, Mr David
More informationEARLY ONLINE RELEASE
EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional
More information